Cogstate Ltd (AU:CGS)
ASX:CGS
Top Page
Cogstate Ltd
(Sydney:CGS)
Select Model
Select Model
Rating:70Outperform
Price Target:
AU$2.50
▼(-1.19% Downside)
Action:UpgradedDate:04/09/26
The score is driven primarily by solid financial quality (high margins and very low leverage) but moderated by the reported revenue and free-cash-flow declines. Technical indicators are supportive with price trading above major moving averages. The latest earnings call adds confidence via improving contracted revenue/backlog and guidance for stronger H2 profitability, while valuation is roughly mid-range with a low dividend yield.
Positive Factors
Strong balance sheet & cash
Minimal leverage and sizable cash provide durable financial optionality. With debt-to-equity at 0.01, equity financing of assets ~74% and $34.1m cash on hand, Cogstate can fund delivery capacity, invest in product development, and withstand trial timing volatility without needing near-term external financing.
Negative Factors
Sharp reported revenue decline
A 34% revenue drop signals structural sensitivity to trial timing and contract recognition. Even with improving backlog, such volatility undermines predictable top-line growth, complicates capacity planning and can delay margin recovery if contract conversion timing remains uneven across reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet & cash
Minimal leverage and sizable cash provide durable financial optionality. With debt-to-equity at 0.01, equity financing of assets ~74% and $34.1m cash on hand, Cogstate can fund delivery capacity, invest in product development, and withstand trial timing volatility without needing near-term external financing.
Read all positive factors
Cogstate Ltd (CGS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$410.38M
Dividend Yield0.88%
Average Volume (3M)355.93K
Price to Earnings (P/E)20.9
Beta (1Y)-0.16
Revenue Growth21.47%
EPS Growth89.09%
CountryAU
Employees147
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.04
Shares Outstanding170,989,670
10 Day Avg. Volume327,690
30 Day Avg. Volume355,934
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)6.26
Price to Sales (P/S)5.90
P/FCF Ratio35.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.18Price Target Upside25.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)AU$59.80M
Cogstate Ltd Business Overview & Revenue Model
Company Description
Cogstate Ltd (CGS) is a global neuroscience technology company focused on the development and commercialization of cognitive assessment tools and solutions. Operating primarily within the healthcare and pharmaceutical sectors, Cogstate specializes...
How the Company Makes Money
Cogstate primarily makes money by providing its cognitive assessment solutions and associated services to organizations running clinical trials and research studies. The core revenue model is business-to-business, where pharmaceutical and biotechn...
Cogstate Ltd Earnings Call Summary
Earnings Call Date:Feb 18, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 26, 2026
Earnings Call Sentiment Positive
The call presented strong commercial momentum and forward visibility: record new trial starts, a 105% jump in sales contracts, solid YoY revenue/backlog growth, expanding channel partnerships, and a healthy cash balance. Short‑term margin pressure and a $0.5M doubtful debt provision were acknowledged, largely driven by deliberate investments in delivery capacity, timing of contract recognition and one‑off adjustments. Management expects margins to recover in H2 as contracted revenue converts and maintains a clear strategy of diversification and technology investment to sustain medium‑term growth.Positive Updates
Significant Growth in Trial Portfolio
Managing 133 clinical trials as at 31 Dec, up 34% year‑on‑year, with a record 42 new trial starts in the December half (most active half-year ever).
Negative Updates
Lower In‑period Revenue Yield and Timing Skew
Revenue yield in the half was lower than historical average due to ~1/3 of new contract value signed in December and a mix of Phase IV/real‑world evidence deals (slower revenue recognition), contributing to H1 being ~8% below the June half.
Read all updates
Q2-2026 Updates
Positive
Negative
Significant Growth in Trial Portfolio
Managing 133 clinical trials as at 31 Dec, up 34% year‑on‑year, with a record 42 new trial starts in the December half (most active half-year ever).
Read all positive updates
Company Guidance
Guidance from the call is that Cogstate expects revenue growth from H1 into H2 and from FY25 into FY26, entering the June half with $21.7m of revenue already contracted for H2 (up 24% y/y) and $27.0m contracted for FY27 (up 13% y/y), with total future contract revenue up 6% y/y and a clinical trials backlog of $92.3m (up 9% y/y); management expects H2 gross margins to recover to roughly 56–59% (with a longer‑term target north of 60%), operating costs to remain relatively constant in H2 while continuing targeted investment in technology and channel partnerships (tech spend YTD ~$2.2m, AI product development ~$0.5–0.6m), and improved profitability in H2 (H1 EBITDA was $6.5m at a 24.3% margin, PBT $5.3m, NPAT $4.5m) supported by $34.1m cash on hand, no debt, and an unchanged annual dividend policy targeting a 20–50% NPAT payout (no interim dividend declared).Cogstate Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
75
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.20M | 50.81M | 66.27M | 60.14M | 62.03M | 43.82M |
| Gross Profit | 26.06M | 30.69M | 37.60M | 12.29M | 21.63M | 10.40M |
| EBITDA | 21.46M | 16.93M | 9.90M | 8.46M | 18.07M | 8.21M |
| Net Income | 14.46M | 10.14M | 5.45M | 5.30M | 10.37M | 7.02M |
Balance Sheet | ||||||
| Total Assets | 68.06M | 64.77M | 57.84M | 81.22M | 84.99M | 68.44M |
| Cash, Cash Equivalents and Short-Term Investments | 34.07M | 35.56M | 45.11M | 43.08M | 44.50M | 31.49M |
| Total Debt | 716.74K | 638.90K | 672.72K | 569.21K | 2.05M | 2.32M |
| Total Liabilities | 16.43M | 16.88M | 25.33M | 24.60M | 37.12M | 39.43M |
| Stockholders Equity | 51.63M | 47.90M | 40.92M | 56.62M | 47.88M | 29.02M |
Cash Flow | ||||||
| Free Cash Flow | 13.58M | 8.40M | 7.12M | -1.53M | 8.54M | 17.24M |
| Operating Cash Flow | 14.16M | 11.48M | 10.00M | 1.76M | 13.45M | 21.61M |
| Investing Cash Flow | -6.84M | -2.24M | -1.68M | -3.29M | -4.91M | -3.52M |
| Financing Cash Flow | -6.51M | -3.79M | -4.91M | -1.33M | 1.05M | -246.11K |
Cogstate Ltd Technical Analysis
Positive
2.53
Price Trends
2.19
Positive
2.29
Positive
2.14
Positive
Market Momentum
<0.01
Negative
63.66
Neutral
50.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CGS, the sentiment is Positive. The current price of 2.53 is above the 20-day moving average (MA) of 2.19, above the 50-day MA of 2.19, and above the 200-day MA of 2.14, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.66 is Neutral, neither overbought nor oversold. The STOCH value of 50.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CGS.
Cogstate Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$410.38M | 20.94 | 29.05% | 0.88% | 21.47% | 89.09% | |
67 Neutral | AU$134.30M | 26.51 | 4.37% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$43.60M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$2.01M | -1.11 | -42.29% | ― | ― | 78.95% | |
43 Neutral | AU$29.26M | -3.13 | -1009.84% | ― | 25.98% | 22.10% | |
40 Underperform | AU$13.36M | -1.71 | -1122.02% | ― | -67.78% | 37.78% |
* Healthcare Sector Average
AU:CGS
Cogstate Ltd
2.40
1.10
84.62%
AU:TD1
Tali Digital
0.04
-0.03
-38.57%
AU:PKY
Opyl Ltd.
0.02
>-0.01
-12.00%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.07
-31.82%
AU:ALC
Alcidion Group Limited
0.10
0.02
25.00%
AU:PCK
PainChek Ltd
0.14
-0.16
-53.18%
Cogstate Ltd Corporate Events
Cogstate Lifts Contracted Revenue as CNS Trial Demand Grows
Apr 7, 2026
Cogstate Ltd, a specialist in CNS clinical trial endpoints and digital cognitive testing, continues to expand its role in neuroscience research by supplying technology and services that improve the accuracy and actionability of cognitive data. The...
Cogstate issues daily update on ongoing on-market share buy-back
Mar 25, 2026
Cogstate Ltd, listed on the ASX under ticker CGS, is an Australian public company with ordinary fully paid shares and an established presence in the equity capital markets. The company actively manages its capital base through on-market transactio...
Cogstate Reports Daily Progress in Ongoing On-Market Share Buy-Back
Mar 24, 2026
Cogstate Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back of ordinary fully paid shares under code CGS. The update, dated 25 March 2026, reports that the company has bought back a cumulative 852,50...
Cogstate Updates Market on Progress of On-Market Share Buy-Back
Mar 22, 2026
Cogstate Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back of ordinary fully paid shares under the code CGS. The company reported that it had repurchased a cumulative total of 744,799 shares prior t...
Cogstate Issues Daily Update on Ongoing On-Market Share Buy-Back
Mar 18, 2026
Cogstate Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The company reported that a total of 743,004 shares had been repurchased before the previous tr...
Cogstate Updates Investors on Progress of On‑Market Share Buy‑Back
Mar 17, 2026
Cogstate Ltd has provided an update on its on‑market share buy‑back program for its ordinary fully paid shares listed on the ASX under the code CGS. The company reported that, as of the latest notification dated 18 March 2026, it had r...
Cogstate Continues On-Market Share Buy-Back With Fresh Daily Purchases
Mar 9, 2026
Cogstate Ltd has provided an update on its ongoing on-market share buy-back of ordinary fully paid shares traded under the ASX code CGS, originally notified in November 2025. The company reported that a total of 565,166 shares had been repurchased...
Cogstate Provides Daily Update on Ongoing On-Market Share Buy-Back
Feb 24, 2026
Cogstate Ltd has issued an updated notification to the ASX regarding its on-market share buy-back program for its ordinary fully paid securities. The latest filing, dated 25 February 2026, confirms that the company continues to execute the buy-bac...
Cogstate Updates Daily On‑Market Share Buy‑Back Activity
Feb 23, 2026
Cogstate Ltd has disclosed an update to its on-market share buy-back program for its ordinary fully paid shares traded on the ASX under the code CGS. The company reported that a total of 180,043 shares had been repurchased before the previous trad...
Cogstate Cancels 180,043 Shares Under On-Market Buy-Back
Jan 14, 2026
Cogstate Ltd, listed on the ASX under the code CGS, has cancelled 180,043 fully paid ordinary shares as part of an on-market share buy-back completed on 14 January 2026. The reduction in issued capital through this buy-back is likely aimed at opti...
Cogstate Sets Date for FY26 Half-Year Results and Investor Webcast
Jan 13, 2026
Cogstate Ltd has scheduled the release of its half-year results for the period ended 31 December 2025 on 19 February 2026, and will host a live webcast and QA for investors on the same day, led by senior executives including the CEO, CFO and Execu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.